期刊文献+

纤溶酶原激活物抑制因子1基因启动子区4G和5G多态基因型分布及其与多囊卵巢综合征的相关性研究 被引量:17

Correlation between 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 gene polymorphism in its promoter region with polycystic ovarian syndrome
原文传递
导出
摘要 目的探讨纤溶酶原激活物抑制因子1(PAI-1)基因启动子区4G及5G的多态基因型分布,及其与多囊卵巢综合征(PCOS)发病的关系。方法应用聚合酶链反应-限制性片段长度多态性技术,检测101例PCOS患者(PCOS组)与42例因男性或单纯输卵管因素不孕患者(对照组)PAI-1基因启动子区4G基因型及5G多态基因型分布,测定并计算两组患者的体重指数、胰岛素抵抗指数、胰岛素敏感指数及自然流产数等临床指标。根据体重指数将PCOS患者分为肥胖者(48例)与非肥胖者(53例)。结果PCOS组PAI-1基因启动子区4G基因型频率为57%(58/101),对照组为38%(16/42);PCOS组5G基因型频率为43%(43/101),对照组为62%(26/42)。两组4G及5G基因型频率分别比较,差异均有统计学意义(P<0.05)。肥胖者胰岛素抵抗指数、胰岛素敏感指数与非肥胖者比较,差异均有统计学意义(P<0.05,P<0.01)。肥胖者4G基因型频率为48%(23/48),非肥胖者为68%(36/53);肥胖者5G基因型频率为52%(25/48),非肥胖者为32%(17/53)。两者4G及5G基因型频率分别比较,差异均有统计学意义(P<0.05)。27例有妊娠史的PCOS患者中,自然流产14例,4G基因型频率为79%(11/14),5G基因型频率为21%(3/14);无自然流产13例,4G基因型频率为38%(5/13),5G基因型频率为62%(8/13),两者4G与5G基因型频率分别比较,差异均有统计学意义(P<0.05)。结论PAI-1基因启动子区4G基因型频率高,可能与PCOS的发病,尤其是与非肥胖者发生PCOS有关,并与PCOS患者的自然流产率高有关。 Objective To investigate the correlation of 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 (PAI-1) gene polymorphism in its promoter region with polycystic ovary syndrome (PCO$). Methods In 101 Chinese PCOS patients and 42 women as control, 4G and 5G polymorphisms of PAI-1 gene were detected with PCR-restriction fragment length polymorphism (RFLP). Pregnant history, body mass index (BMI), waist-hip ratio (WHR) were collected and Homastasis Model Assessment score for insulin resistant (Homa-IR) and insulin sensitive index (ISI) in PCOS groups were calculated . Results The distributions of PAI-1 gene polymorphisms 4G type (4G/4G genetype) and 5G type (SG/SG,4G/SG genetype) were different between the PCOS group and the control. The PCOS group had higher 4G type 57% (58/101) distribution than that of the control group 38% (16/42) ;SG type is vise verse ( P 〈 0.05 ). PCOS patients were divided into obese and non-obese sub-groups according to BMI. There were significant lower Homa -IR and higher ISI in non-obese subgroup than that in obese group( P 〈0. 05 ; P 〈0.01 ). 68% (36/53)4G type distribution in the non-obese is higher than that [48% (23/48) ] in obese sub-group(P 〈0. 05). There were higher 4G type distribution 79% (11/14)and lower 5G type distribution 21% (3/14) in spontaneous miscarriage group than that of in non-spontaneous miscarriage group 38% (5/13) and 62% (8/13) among patients who impregnated at least once (n = 27,P〈 0.05).Conclusion PAI-1 gene polymorphism 4G genetype may be correlated with PCOS in Chinese women, especially in PCOS patients with non-obese PCOS and spontaneous miscarriage.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2005年第8期528-531,共4页 Chinese Journal of Obstetrics and Gynecology
基金 国家自然科学基金资助项目(39300136 30270512)
  • 相关文献

参考文献9

  • 1李秀均.胰岛素抵抗综合征[M].北京:人民卫生出版社,2001..
  • 2管立学,季祥武,王敬先,张爱元,张言镇,赵立梅.纤溶酶原激活剂抑制物-1基因启动子区-6754G/5G多态性与中国人冠心病的关联研究[J].中华医学遗传学杂志,2002,19(5):393-396. 被引量:17
  • 3陈子江,石玉华,赵跃然,李媛,唐蓉,赵力新,张中和.胰岛素受体基因多态性与多囊卵巢综合征发病的关系[J].中华妇产科杂志,2004,39(9):582-585. 被引量:30
  • 4Orio F Jr, Palomba S, Cascella T, et al. ls plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online,2004 ,9 :505-510.
  • 5Diamanti-Kandarakis E, Palioniko G, Alexandraki K, et al. Theprevalence of 4GSG polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol, 2004,150:793-798.
  • 6Tarkun I, Canturk Z, Arslan BC, et al. The plasminogen activator system in young and lean women with polycystic ovary syndrome.Endocr J, 2004 ,51:467-472.
  • 7楚新梅,何秉贤.纤溶酶原激活物抑制剂-1基因多态性与代谢综合征[J].中华心血管病杂志,2004,32(2):184-186. 被引量:13
  • 8Juhan-Vague I, Morange PE, Frere C, et al. The plasminogen activator inhibitor-1 675 4G/SG genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost. 2003 , 11:2322-2329.
  • 9Glueck C J, Wang P, Goldenberg N, et aL Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin,metformin. Clin Appl Thromb Hemost,200d, 10:323-334.

二级参考文献17

  • 1丁国宪 沈捷 陈家伟 等.纤溶酶原激活剂抑制物-1基因启动子多态性与2型糖尿病伴发冠心病的关系[J].中华老年医学杂志,1998,17:348-351.
  • 2Patel K,Coffler MS,Dahan MH,et al.Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.Clin Endocrinol (Oxf),2004,60:67-74.
  • 3Asuncion M,Calvo RM,San Millan JL,et al.A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.J Clin Endocrinol Metab,2000,85:2434-2438.
  • 4Bernard L,Christin-Maitre S,Basille C,et al.Insulin resistance and polycystic ovary syndrome.Gynecol Obstet Fertil,2003,31:109-116.
  • 5Diamanti-Kandarakis E,Kandarakis HA.Conservative management of gynecologic diseases: insulin sensitizing agents in polycystic ovary syndrome.Ann N Y Acad Sci,2003,997:322-329.
  • 6Dunaif A,Thomas A.Current concepts in the polycystic ovary syndrome.Annu Rev Med,2001,52:401-419.
  • 7Siegel S,Futterweit W,Davies TF,et al.A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome.Fertil Steril,2002,78:1240-1243.
  • 8The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod,2004,19:41-47.
  • 9Barontini M,Garcia-Rudaz MC,Veldhuis JD.Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome.Arch Med Res,2001,32:544-552.
  • 10VrbIkova J,Cibula D,Dvorakova K,et al.Insulin sensitivity in women with polycystic ovary syndrome.J Clin Endocrinol Metab,2004,89:2942-2945.

共引文献66

同被引文献308

引证文献17

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部